Latest news with #Empagliflozin
&w=3840&q=100)
Business Standard
16-07-2025
- Health
- Business Standard
Generic glut leads to numerous price actions on diabetes medications
The Centre may be looking at fixing the retail price for several combinations of antidiabetic medications such as empagliflozin, after a rise in generic versions of the drug led to subsequent price drops. While price revision lists by the National Pharmaceutical Pricing Authority (NPPA) include several diabetes drugs, combinations of empagliflozin have been prominently mentioned in the past three months. In June 2025, the authority fixed retail prices of 25 variations of the drug marketed by different companies. This figure was 36 and 18 combinations in April and May, respectively, indicating that many generic brands have come up since the drug went off-patent in March this year. Originally made by German drugmaker Boehringer Ingelheim, the molecule saw the entry of big Indian pharmaceutical players such as Mankind, Alkem, and Torrent within days of losing its patent protection. While the last count was at about 100 new brands, experts believe that many more are expected to be launched. Empagliflozin is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor that lowers blood sugar in adults with Type 2 diabetes. This class of drugs works by preventing glucose reabsorption in the kidneys, leading to increased sugar excretion through urine, and also provides cardiovascular and renal benefits. Amit Chhabra, senior consultant, Department of Diabetes and Endocrinology at Yashoda Medicity, said that SGLT2 is a very commonly prescribed medication currently, and is used in 60-70 per cent of diabetes cases in most outpatient departments. The generic brand boom for empagliflozin has also led to a rise in sales in the past three months. According to data from market research firm Pharmarack, the combined sales of empagliflozin plain plus its combinations with other key molecules such as sitagliptin, linagliptin, and metformin increased from ₹51 crore in March 2025 to ₹66 crore in June 2025 — a 29 per cent rise. 'The unit sales also doubled from 1.95 million units in March this year to 3.46 million units in June,' Sheetal Sapale, vice-president (commercial) at Pharmarack, said. The price fixation of drug combinations also comes after several combinations of the antidiabetic saw a price drop of around 85 per cent after the molecule went off-patent. For example, the maximum retail prices for the plain drug fell from ₹60–70 per tablet to ₹5–15 within a month of patent loss. With over 100 million diabetics in India and rising demand for antidiabetic drugs, the ongoing price drops are expected to make these treatments more affordable and accessible to a broader patient base. Chhabra said that competition rises as many pharmaceutical companies launch the same drug under different brands with competitive costs. 'Another issue that cannot be ignored is the drastic deterioration of manufacturing quality and standards to meet the cost of drugs,' he added.
Mint
09-06-2025
- Business
- Mint
Glenmark to launch cancer drug Zanubrutinib in India
New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name Brukinsa. It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said. The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at ₹ 1,600.85 apiece on BSE. In March, Glenmark Pharmaceuticals had launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)''Glempa-L (Empagliflozin 10/25 mg Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes mellitus with established cardiovascular disease more effectively," Glenmark Pharmaceuticals President and Head of India Formulations Business Alok Malik had said.
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Mankind Pharma Q4: Profit drops 10%, revenue up 27% on domestic growth
Delhi-based Mankind Pharma on Wednesday reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25) at ₹424.65 crore from ₹476.59 crore in the same period last financial year. Mankind's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. Commenting on the results, Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. According to the company, its share in the domestic market increased from 4.4 per cent in March 2024 to 4.8 per cent as of March 2025. It was on account of BSV acquisition and leadership in the gynaecology segment. Mankind had completed the acquisition of 100 per cent stake in BSV for ₹13,768 crore in October 2024. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. Mankind's consumer healthcare segment also reported a revenue growth of 14 per cent in Q4. The export business witnessed a growth of 100 per cent in the March quarter. It was driven by an increase in the base business and launches in the past one-two years, among others. The company declared its results after market hours. On Wednesday, Mankind Pharma's share went down marginally by 0.69 per cent, ending the day's trade at ₹2,533.03 on the BSE.
Time of India
08-05-2025
- Health
- Time of India
Generic versions of key diabetic drug in market double in a month
In less than two months after diabetes drug Empagliflozin went off patent, Indian branded generic players have crowded the market with their versions of the product leading to a month-on-month doubling in the number of players and brands flooding the market in April. #Operation Sindoor Live Updates| From Sindoor to showdown? Track Indo-Pak conflict as it unfolds India hits Lahore's Air Defence Radars in proportionate response Pakistan tried to hit military targets in these 15 Indian cities, New Delhi thwarts strikes Nearly 147 brands of the drug and 37 companies are in the market now, up from 86 brands and 19 companies in March, according to data from industry tracker and market researcher PharmaTrac. Doctors said that an increasing number of anti-diabetic drugs going off patent-with Empagliflozin being the latest-is good for patients and medical practitioners as it makes anti diabetes drugs more affordable in India where cases of diabetes are rising. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Don't Miss The Top Packaging Trends Of 2024, Enhnace Your Brand With The Latest Insights Packaging Machines | Search Ads Search Now Undo Empagliflozin-which was Boehringer Ingelheim's innovator drug sold under the brand name Jardiance-went off patent mid-March. It is used to improve glucose control in people with Type 2 diabetes. Live Events "With almost 150 brands and 40 companies jumping in the Empagliflozin off patent opportunity and volume sales picking up steeply in the last two months, every player in the IPM (Indian pharmaceutical market) looks like geared up to make the most of this opportunity," said Sheetal Sapale, vice president, commercial, PharmaTrac. "Most of the innovator molecules (used to treat Type 2 diabetes) in SGLT 2 (Sodium-Glucose Co-Transporter-2) and DPP4 i (Dipeptidyl peptidase-4 inhibitors) have gone off patent... creating many affordable options available to eligible Indian masses through branded generics ," she added. Empagliflozin is an SGLT-2 inhibitor . Others in the same group include dapagliflozin-whose patent expired a couple years ago leading to nearly 200 generic brands coming into the market. Companies such as Alkem Laboratories , Glenmark Pharmaceuticals and Mankind Pharma launched their versions of Empagliflozin, and slashed prices to about ₹5 per unit, which is 80-90% lower than the innovator's prices. "Ever since dapagliflozin has gone off patent, many more people have access to it has become cheaper. Empagliflozin is also similar to a good medicine for sugar, gives some protection to the heart and kidney too," said Dr David Chandy, director-endocrinology & diabetology at Sir H N Reliance Foundation Hospital and Research Centre. More such molecules going off patent increases the reach to larger populations. "Earlier when only the innovators had these molecules, maybe 2-5% of India's diabetic population could afford it, now the entire diabetic population can afford it," said Chandy. Empagliflozin is a ₹745 crore market today with plains contributing to almost 45% in terms of value as well as quantity. Empagliflozin plain and Empagliflozin plus Linagliptin contribute nearly 80% of this. "In the long-term, more and more affordable medication options are good for patients with the cases of diabetes spiralling in the country and doctors have more ammunition or options for treatment now compared to 5-10 years back," said Chandy. "What will be interesting in the diabetes scenario is that in the next six months, once semaglutide goes off patent, there will be a paradigm shift for diabetes treatment once it is available at a low price," he said.
BBC News
29-01-2025
- Health
- BBC News
Post-op treatment blamed for Middlesbrough woman's diabetic coma
A woman who fell into a diabetic coma following cancer surgery says a hospital trust must "show accountability" for what Ashton says she flagged her condition "every step of the way" before undergoing a major operation at Middlesbrough's James Cook University Tees Hospitals NHS Foundation Trust (STHNFT) said it was likely her coma was linked to the post-operative administration of a medication known to carry the risk of diabetic ketoacidosis (DKA), a dangerous complication of trust said it was taking action with the delivery of "bespoke training" to surgical staff on diabetes management. Mrs Ashton, who has the genetic MODY3 form of diabetes, said she felt abandoned and that "nobody was paying attention" to her condition or concerns, during her time in hospital in October the days after the operation, she said she had bouts of vomiting and was unable to keep prescription medication this period, sick bowls were often left out of reach and some calls for help went unheeded, she Ashton said repeated requests for alternatives to oral medication went unmet and signs of DKA were missed until her condition had deteriorated. 'Extreme vulnerability' Her husband Colin Ashforth said he raised concerns with nursing staff when he visited on 8 October and found her "barely conscious".He said he was told his wife was trust said DKA was diagnosed later that day when the ward's nursing team noticed a deterioration in her said "all appropriate actions" were then taken to manage DKA, with a doctor requesting a follow-up visit from a diabetic specialist the visit did not happen for another three days, because it coincided with a weekend. Mrs Ashton said she now has to take insulin and her faith in the health service was "completely undermined" after being "let down at a time of extreme vulnerability"."When you go into hospital, you are handing yourself over to who you believe and hope are caring professionals," she said."I was left with an overriding sense of abandonment and I continue to struggle with PTSD as a result of that." Action pledged Mrs Ashton said medical and nursing staff were "dismissive" of her concerns, inconsistent in their record keeping and there was inadequate catering for diabetics. The trust said it found DKA was likely to have been caused by "poor oral intake" and the administration of the drug Empagliflozin, an anti-hyperglycemic medication associated with an increased risk of the condition. Delays and shortcomings in the trust's handling of the complaint were reported to the Parliamentary and Health Service Ombudsman and the hospital trust sent its conclusion to its investigation to Mrs Ashton last correspondence seen by the BBC, group chief executive officer Stacey Hunter and site medical director Dr Diane Monkhouse said they were "very sorry" that Mrs Ashton's experience had caused her distress.A letter outlining action to be taken said feedback would be shared with staff, and at a directorate meeting addressing a lack of information given to the patient and her also said feedback of the patient's opinion of staff being "dismissive" would be shared and an audit of discharge letters would be carried out. Call for awareness Mrs Ashton said she was not satisfied with the outcome of her complaint and wanted the trust's CEO to apologise to her in said: "This was a diabetic problem but I was in hospital for a cancer problem, so the focus was on the general surgery, not diabetes."It's about education and awareness, because diabetes has such a fundamental impact on your total system."
